United Kingdom· GB-APID-44886311000001109
Briumvi 150mg/6ml concentrate for solution for infusion vials
A ublituximab product containing ublituximab, registered in United Kingdom by Neuraxpharm UK Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Ublituximab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG14 (ublituximab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Ublituximab · ATC L04AG14
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Ublituximab
- Manufacturer
- Neuraxpharm UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AG14
- ATC class
- Ublituximab
- Defined daily dose
- 2.68 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin8436027473145
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ublituximab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBRIUMVINeuraxpharm Pharmaceuticals, S.L., Barcelona
- SwitzerlandBriumvi
- FinlandBriumviNeuraxpharm Pharmaceuticals S.L.
- IrelandBriumvi 150 mg Concentrate for solution for infusionNeuraxpharm Pharmaceuticals S.L.
- IcelandBriumviNeuraxpharm Pharmaceuticals S.L.
- NetherlandsBriumvi 150 mg concentraat voor oplossing voor infusieNeuraxpharm Pharmaceuticals S.L.
- NorwayBriumviNeuraxpharm Pharmaceuticals, S.L.
- PolandBriumviNeuraxpharm Pharmaceuticals, S.L.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Briumvi
- Liechtenstein · Briumvi
- Norway · Briumvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/68c4bcb3-2df0-4940-a76e-d92bd242b527 GET /v1/drugs/68c4bcb3-2df0-4940-a76e-d92bd242b527?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "44886311000001109",
"desc": "Briumvi 150mg/6ml concentrate for solution for infusion vials (Neuraxpharm UK Ltd)",
"form": "Solution for infusion",
"vpid": "44923911000001101",
"source": "dmd",
"vtm_id": "44889911000001101",
"strength": "25 mg",
"substance": "Ublituximab",
"ingredient": "Ublituximab",
"supplier_code": "37898411000001108"
}See everything about ublituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.